ArticleTranslational vision science & technology2026
Targeting the Hedgehog Signaling Pathway in the Retina Using Quercetin-Loaded Lipid Nanoparticles for Myopia Control.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ion‑Responsive in situ Gel of Quercetin‑Loaded PEGylated Liposomes for Anti‑inflammatory Treatment of Dry Eye Disease.International journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Myopia is emerging as a major global health concern, with the prevalence increasing to nearly epidemic levels. Currently, its pathogenesis and treatment methods still must be further studied. This study aimed to explore the therapeutic efficacy of quercetin in myopia control and attempt to decipher the underlying mechanism. Methods: A quercetin-loaded liposome (QLS) delivery system was prepared by a thin-film dispersion method assisted with ultrasonication. Guinea pigs with form-deprivation myopia were used to demonstrate the therapeutic efficacy of QLSs. The retinas were collected to verify the underlying mechanisms through proteomics, digital capillary western blotting, and multicolor immunofluorescence staining. Furthermore, the interactions between quercetin and target proteins were verified through molecular docking. Finally, blood biochemical indexes and morphological changes in vital organs were compared to evaluate the biosafety of QLSs. Results: The obtained QLSs displayed a uniform size distribution with an average diameter of 274.06 ± 26.98 nm (polydispersity index [PDI] = 0.202) and a negative surface charge of -15.0 mV. Notably, liposomal formulation markedly enhanced the water solubility and bioavailability of quercetin, facilitating effective myopia control at low doses. QLSs exhibit a sustained release effect and excellent in vivo biosafety. Mechanistically, QLSs inhibited activation of the hedgehog signaling pathway, suppressing the elongation of axial length. Conclusions: QLSs could suppress experimental myopia progression by inhibiting the activation of hedgehog signaling pathway, offering a promising approach for preventing myopia. Translational Relevance: QLSs exhibited excellent aqueous solubility and bioavailability, enabling low-dose administration with significant efficacy, thereby presenting great prospects for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.